Company: PCRX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001104659-25-041219
Chunk: 18

Company: Pacira BioSciences, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 18
---
 noted above guide our pay decisions in combination with multiple other factors. The actual positioning of compensation relative to targeted benchmarks is influenced by performance, tenure, organizational criticality, and internal equity. Long-term incentive compensation is achieved with a mix of the cash LTIP and longer-term equity awards. • Target awards for our cash LTIP were equal to our named executive officers’ annual incentive bonus targets as of the beginning of the performance year. For 2024, the cash LTIP was achieved at 85.0% of target based on the achievement of net revenue and Adjusted EBITDA (as defined herein) goals relative to pre-established performance goals. • In connection with his January 2024 hire, our chief executive officer (CEO), Frank D. Lee, received an equity award that was awarded approximately 75% in stock options and 25% in restricted stock units (RSUs), as did Shawn Cross, our chief financial officer (CFO), in connection with his October 2024 hire. The board selected this equity mix in accordance with standard practices for new hires to align with our objective of maximizing stockholder value. • For our other named executive officers, the 2024 equity grant was awarded 100% in RSUs to address potential retention concerns during a time of significant changes in the Company’s business, combined with a lack of retentive value from prior stock option awards at such time. 2024 Equity Grant Mix Total Target Compensation Mix These charts represent the target values granted to our CEO, Frank D. Lee and the average of our other named executive officers in 2024 (excluding David Stack, our former CEO and Chairman and Charles A. Reinhart, III, our former CFO, who were known to be departing the organization, and Lauren Riker, who was our interim CFO for approximately three weeks). To incentivize them to accept their offers of employment with the Company in the context of a highly competitive market, Messrs. Lee and Cross received larger equity grants in connection with their hirings than would be targeted for them in subsequent years. These targeted values also exclude special retention grants made to Kristen Williams and Daryl Gaugler and a grant to Jonathan Slonin of stock options and RSUs in connection with his promotion to Chief Medical Officer. Actual amounts earned can be found in “Compensation Discussion and Analysis” beginning on page 51. 14 | investor.pacira.com

TABLE OF CONTENTS

| ​ | ​ | CorporateGovernanceand BoardMatters | ​ |

|